A Study to Evaluate Overall Health, Physical Activity, and Joint Outcomes in Participants With Severe or Moderate Hemophilia A Without Factor VIII Inhibitors on Emicizumab Prophylaxis

To be considered for this study, you need to have been diagnosed with either severe or moderate haemophilia A. An important point is that you must not have certain antibodies called 'Factor VIII inhibitors', and you shouldn't have developed them in the last five years. You also need to have been on another regular haemophilia treatment (Factor VIII prophylaxis) for at least 24 weeks before the study starts.

There are also some health checks to make sure the study is a good fit for you, such as having healthy blood, liver, and kidney function. If you are a woman who could become pregnant, you would need to agree to use effective contraception or avoid sexual intercourse during the study and for 24 weeks afterwards.

You wouldn't be able to join if you have another bleeding disorder, have taken emicizumab before, or are planning to have certain joint procedures. Also, if you've had a joint procedure recently (within 2 years) or if it was more than 3 years ago but you're still experiencing pain in that joint, you might not be suitable.

If you decide to take part, you will switch from your current haemophilia treatment to emicizumab. The study involves regular visits to the clinic where doctors and nurses will check your overall health, ask about your activity levels, and assess your joint health. You might have blood tests and physical examinations to help track how you're doing on emicizumab. The total duration of your participation in this study would be decided, but for a Phase IV study like this, it generally involves ongoing monitoring and possibly collecting data over a longer period to understand the long-term effects. The research team will explain the full schedule of visits and assessments.